MedPath

Ganzhou Hemay Pharmaceutical Co., Ltd.

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

10

Active:1
Completed:4

Trial Phases

3 Phases

Phase 1:7
Phase 2:2
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials

Phase 1
7 (70.0%)
Phase 2
2 (20.0%)
Phase 3
1 (10.0%)

Pharmacokinetic Interactions Between Hemay005 Tablets and Midazolam Maleate Tablets

Phase 1
Recruiting
Conditions
Psoriasis
Interventions
First Posted Date
2024-09-24
Last Posted Date
2025-03-19
Lead Sponsor
Ganzhou Hemay Pharmaceutical Co., Ltd
Target Recruit Count
20
Registration Number
NCT06610890
Locations
🇨🇳

Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Bioequivalence Test of Hemay005 Tablets

Phase 1
Completed
Conditions
Psoriasis
Interventions
First Posted Date
2024-09-24
Last Posted Date
2025-03-18
Lead Sponsor
Ganzhou Hemay Pharmaceutical Co., Ltd
Target Recruit Count
28
Registration Number
NCT06610903
Locations
🇨🇳

Wuhan Central Hospital, Wuhan, Hubei, China

To Evaluate the Pharmacokinetics of Hemay005 Tablets in Patients With Renal Impairment

Phase 1
Recruiting
Conditions
Psoriasis
Interventions
First Posted Date
2024-04-23
Last Posted Date
2025-03-19
Lead Sponsor
Ganzhou Hemay Pharmaceutical Co., Ltd
Target Recruit Count
24
Registration Number
NCT06380153
Locations
🇨🇳

Union Hospital of Tongji Medical College; Huazhong University of Science and Technology, Wuhan, Hubei, China

To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage

Phase 1
Recruiting
Conditions
Psoriasis
Interventions
First Posted Date
2024-04-19
Last Posted Date
2025-03-19
Lead Sponsor
Ganzhou Hemay Pharmaceutical Co., Ltd
Target Recruit Count
24
Registration Number
NCT06376474
Locations
🇨🇳

Union Hospital of Tongji Medical College; Huazhong University of Science and Technology, Wuhan, Hubei, China

A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease

Phase 3
Recruiting
Conditions
Behçet's Disease
Interventions
Drug: Placebo
First Posted Date
2023-11-24
Last Posted Date
2025-04-08
Lead Sponsor
Ganzhou Hemay Pharmaceutical Co., Ltd
Target Recruit Count
162
Registration Number
NCT06145893
Locations
🇨🇳

Beijing Friendship hospital capital medical hospital, Beijing, Beijing, China

🇨🇳

Peking university first hospital, Beijing, Beijing, China

🇨🇳

Peking University People's Hospital, Beijing, Beijing, China

and more 19 locations
  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.